newsfilter
← Latest News
Business Wire·

Infinity Pharmaceuticals Reports First Quarter 2022 Financial Results

– MARIO-4, the first eganelisib registration-enabling trial, in front-line metastatic triple negative breast cancer (TNBC) expected to initiate by year-end 2022 – – MARIO-P, a clinical program designed to expand eganelisib development in additi